Florida’s dengue outbreak highlights the importance of recognizing symptoms, identifying warning signs, and preventing mosquito bites. Ubong Johnson, MD, explains local transmission, diagnostic testing, treatment, and practical prevention measures.
|Articles|January 26, 2005
AHF Welcomes FDA's First-Ever Approval of Generic AIDS Drugs
Advertisement
LOS ANGELES -- AIDS Healthcare Foundation (AHF) the largest U.S.-based AIDS organization with free AIDS treatment clinics in the United States, Africa, Central America and Asia, welcomed the news that the United States Food and Drug Administration (FDA) has approved generic AIDS drugs produced by South Africas Aspen Pharmacare. The move makes the pharmaceutical manufacturer the first in the world to receive approval from the U.S. government agency for its generic anti-retroviral drugs to fight AIDS. The FDAs action also clears the way for Aspens far less costly AIDS drugs -- specifically, its combination of lamivudine/zidovudine and nevirapine tablets -- to be utilized in Presidents Bushs ambitious $15 billion, 5-year Presidents Emergency Plan For AIDS Relief (PEPFAR). The President had made FDA approval a requirement of any generic medicines that PEPFAR uses in its global treatment efforts.
Todays FDAs approval of Aspens generic life-saving AIDS drugs could truly save hundreds of thousands of lives, said Michael Weinstein, president of AIDS Healthcare Foundation. This approval now allows PEPFAR to utilize Aspens generic AIDS drugs in its global treatment efforts to get two million people in treatment. We strongly urge the President and PEPFAR officials to quickly incorporate these effective, yet far less costly anti-retroviral drugs into PEPFARs treatment programs in Africa and the Caribbean. We believe that three times as many people can be treated -- and three times as many lives saved -- by using safe, effective and far cheaper generic AIDS drugs.
The approval is for Aspens generic equivalent of the most widely used triple cocktail combination of lamivudine/zidovudine (branded as GSKs Combivir) and nevirapine (branded as Boehringer Ingelheims Viramune) tablets in conventional adult dosages.
The FDA approval now means that Aspen has become the first accredited generic supplier to have access to the Presidents Emergency Plan for Aids Relief fund.
Source: AIDS Healthcare Foundation
Advertisement
Related to this article
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
An unexplained death at a Russian plague research institute has prompted international scrutiny. The incident raises questions about laboratory safety, transparent reporting, and infection prevention preparedness while the cause remains unconfirmed.
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.
This week's coverage in Infection Control Today centered on a common thread: the systems, partnerships, and data that let infection prevention teams catch problems before patients are harmed.
UPMC’s genomic surveillance initiative earned national recognition for patient safety. Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, explains how the award could help infection preventionists secure leadership support and sustainable funding for earlier outbreak detection.
Knowing the protocol is only the beginning. In The Clean Bite, Sherrie Busby explores how explaining the why, addressing staff concerns, and creating clear procedures can help dental teams make infection control part of everyday practice.
Advertisement
Advertisement